API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/en/news-release/2020/07/08/2059504/22558/en/ViralClear-Pharmaceuticals-partners-with-Albany-Molecular-Research-Inc-on-the-manufacture-of-merimepodib-active-pharmaceutical-ingredient-development-for-the-potential-treatment-of.html
https://www.globenewswire.com/news-release/2020/05/18/2034956/0/en/FDA-Clears-the-Investigational-New-Drug-Application-to-Enable-the-Phase-II-Trial-of-ViralClear-s-Merimepodib-Oral-Solution-to-Treat-Adult-Patients-with-Advanced-COVID-19-to-Proceed.html
https://ir.biosig.com/press-releases/detail/199/viralclear-publishes-in-f1000-research-in-vitro-data
https://markets.businessinsider.com/news/stocks/viralclear-submits-in-vitro-data-on-merimepodib-and-remdesivir-synergistic-activity-against-the-covid-19-novel-coronavirus-to-a-peer-reviewed-journal-1029150595
https://www.globenewswire.com/news-release/2020/04/23/2021020/0/en/ViralClear-Publishes-Comparative-In-Vitro-Data-on-Merimepodib-and-Remdesivir-Activity-Against-the-COVID-19-Novel-Coronavirus-in-F1000-Research.html